The procurement and perfusion method, areas that are rapidly evolving, will likely play a role in the success of DCD transplants.

When the heart’s muscle is weakened or injured due to a heart attack, it can make it hard for the heart to pump enough blood ...

LMH Health is adding innovative procedures that could make a big difference for cardiac patients in our community. From the ...

After decades of misdiagnosis and missed signals, researchers are finally starting to close the gender gap that has long ...

Heart disease remains the leading cause of death for women. Despite advancements in awareness and research, gaps remain in ...

Heart failure admissions and re-admissions remain a major cost and capacity challenge for Australian hospitals. ... Read More ...

A nephrology resident begins a weekend call shift managing dialysis patients and kidney failure cases. One patient misses two ...

Further database analysis is needed to create accurate risk prediction models for surgical morbidity and mortality to aid ...

Zenocutuzumab--zbco, marketed as BIZENGRI (R), received Breakthrough Therapy Designation from the FDA in October 2025 and was granted accelerated approval in December 2024 for adults with advanced ...

HCM is a genetic disease, usually caused by mutations in sarcomere proteins such as myosin, actin, tropomyosin, and myosin-binding protein C.

Myqorzo (aficamten) is a new therapy for oHCM, improving functional capacity and symptoms, with an annual cost of $108,400. The Myqorzo & You program provides personalized support, including insurance ...

Health News Our heart, a vital organ, functions tirelessly from birth until death. It beats approximately 1,15,000 times a ...